Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors

Blood. 2020 Feb 13;135(7):510-513. doi: 10.1182/blood.2019003570.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives
  • Aged
  • Female
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / immunology
  • Macrophages / pathology
  • Male
  • Middle Aged
  • Phenotype
  • Piperidines
  • Pyrazoles / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Remission Induction
  • Treatment Outcome

Substances

  • Piperidines
  • Pyrazoles
  • Pyrimidines
  • ibrutinib
  • Adenine